Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Company Profile Akari Therapeutics Plc AKTX

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.


Company Profile & Information (NDAQ:AKTX)

Showcase News Releases

Showcase news

SoLVBL Solutions
SoLVBL Solutions Inks Its First Technology Integration Pilot Agreement with a Leading UK Multi Branded CBD Health & Wellness Group to Deploy Its Flagship Q by SoLVBL Cybersecurity Technology
NV Gold Corp
NV Gold Completes Initial Drilling Program at Sandy; Initiates First Stage Drilling Program at the Pickhandle Gold Project
Charbone Hydrogen
CHARBONE HYDROGÈNE announces signature of a memorandum of understanding with the PORT OF BAIE-COMEAU and the CITY OF BAIE-COMEAU for the development of a green hydrogen production plant

More Showcase News Releases »